Skip To Main Content
Juying Wei on Muck Rack

Juying Wei

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Juying

Contact Juying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)

|
By Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, Keshu Zhou, Huijing Wu, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Wenyu Li, Li’e Lin, Qing Xiao, Hongmei Jing, Meifang Zheng, Hongyu Zhang, Yuhuan Gao, Da Gao, Lijia Chen, Jie Jin, Juying Wei, Erhua Wang
| Nature Verified
Abstract Patients with peripheral T cell lymphoma (PTCL) who achieved tumor response with first-line standard therapy were at high risk of disease relapse. We explored golidocitinib (150 mg once daily) as maintenance therapy for this group of patients (JACKPOT26, NCT06511869). This study included two cohorts: patients achieving a complete response (Cohort 1 (CR), N = 30) and a partial response (Cohort 2 (PR), N = 18) during induction stage.
Open in Who Shared Issue with article?
See all 1 articles